Dirlotapide

This image is provided by the National Library of Medicine.

WikiDoc Resources for Dirlotapide
Articles
Most recent articles on Dirlotapide Most cited articles on Dirlotapide Review articles on Dirlotapide Articles on Dirlotapide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dirlotapide Images of Dirlotapide Photos of Dirlotapide Podcasts & MP3s on Dirlotapide Videos on Dirlotapide
Evidence Based Medicine
Cochrane Collaboration on Dirlotapide Bandolier on Dirlotapide TRIP on Dirlotapide
Clinical Trials
Ongoing Trials on Dirlotapide at Clinical Trials.gov Trial results on Dirlotapide Clinical Trials on Dirlotapide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dirlotapide NICE Guidance on Dirlotapide NHS PRODIGY Guidance FDA on Dirlotapide CDC on Dirlotapide
Books
Books on Dirlotapide
News
Dirlotapide in the news Be alerted to news on Dirlotapide News trends on Dirlotapide
Commentary
Blogs on Dirlotapide
Definitions
Definitions of Dirlotapide
Patient Resources / Community
Patient resources on Dirlotapide Discussion groups on Dirlotapide Patient Handouts on Dirlotapide Directions to Hospitals Treating Dirlotapide Risk calculators and risk factors for Dirlotapide
Healthcare Provider Resources
Symptoms of Dirlotapide Causes & Risk Factors for Dirlotapide Diagnostic studies for Dirlotapide Treatment of Dirlotapide
Continuing Medical Education (CME)
CME Programs on Dirlotapide
International
Dirlotapide en Espanol Dirlotapide en Francais
Business
Dirlotapide in the Marketplace Patents on Dirlotapide
Experimental / Informatics
List of terms related to Dirlotapide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.

It works as a selective microsomal triglyceride transfer protein (MTTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.

It is supplied as an oral solution. It is not intended for use in humans, cats, or parrots.

On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs. Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog's weight.